Under one in 10 patients that would benefit from obesity jabs such as Wegovy are able to get them, states the WHO as it publishes its inaugural recommendations on the drugs.
Considering in excess of 1,000,000,000 individuals worldwide currently obese, it is advocating for broader and more equitable access to these injectable treatments.
According to forecasts, in excess of 2,000,000,000 could be living with obesity by 2030 if no action is taken.
"Our new guidelines affirms that obesity is a lifelong illness that can be addressed with holistic and ongoing support," said the agency's head Tedros Adhanom Ghebreyesus.
Substantial prices, insufficient output, and supply-chain constraints are significant obstacles to broad access to the treatments that can assist patients in reducing considerable body mass, explains the organization.
Skinny Jab Shortage
Even under the current best projected case, the supply of GLP-1 therapies might only reach approximately 100 million people – fewer than 10% of eligible patients, as stated by the WHO.
The advice urges governments and firms to increase access, via measures like voluntary licensing.
The intellectual property rights on the active ingredient – the core component of a leading brand – is scheduled to end in multiple nations in 2026.
How Obesity Drugs Operate
These medications mimick a body's own hormone to delay gastric emptying, curb appetite and boost feelings of fullness so individuals eat less.
People typically see weight reduction after several weeks of beginning the regular doses.
Evidence indicates people may regain a significant portion a year later of stopping the treatment, as their normal appetite resume.
To be carrying excess weight increases your chance for experiencing health problems, like type 2 diabetes, heart disease, brain attack, and certain malignancies.
Obesity impacts people in countries worldwide and was linked to millions of fatalities worldwide in 2024, according to the health agency.
